Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other equities analysts also recently commented on KPTI. ValuEngine upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and set a $19.00 target price (up previously from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Saturday, June 24th. Finally, Robert W. Baird restated an “outperform” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $14.56.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 0.44% during midday trading on Friday, hitting $9.05. The company had a trading volume of 262,242 shares. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63. The company’s market cap is $426.60 million. The stock’s 50-day moving average price is $8.88 and its 200-day moving average price is $9.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. Karyopharm Therapeutics’s quarterly revenue was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.84) earnings per share. On average, equities research analysts forecast that Karyopharm Therapeutics will post ($2.68) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “BidaskClub Upgrades Karyopharm Therapeutics Inc. (KPTI) to Hold” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/27/bidaskclub-upgrades-karyopharm-therapeutics-inc-kpti-to-hold.html.

A number of large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in Karyopharm Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 5,780,553 shares of the company’s stock worth $74,223,000 after buying an additional 54,137 shares in the last quarter. Palo Alto Investors LLC boosted its stake in Karyopharm Therapeutics by 1.8% in the second quarter. Palo Alto Investors LLC now owns 3,467,575 shares of the company’s stock worth $31,382,000 after buying an additional 61,100 shares in the last quarter. Vanguard Group Inc. boosted its stake in Karyopharm Therapeutics by 31.1% in the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after buying an additional 384,658 shares in the last quarter. Tekla Capital Management LLC boosted its stake in Karyopharm Therapeutics by 25.0% in the second quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock worth $6,848,000 after buying an additional 151,455 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Karyopharm Therapeutics by 25.8% in the first quarter. JPMorgan Chase & Co. now owns 518,610 shares of the company’s stock worth $6,660,000 after buying an additional 106,234 shares in the last quarter. 57.58% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.